Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Long-Term Investments: 2024-2025

Historic Long-Term Investments for Stoke Therapeutics (STOK) over the last 1 years, with Sep 2025 value amounting to $80.3 million.

  • Stoke Therapeutics' Long-Term Investments rose 168.15% to $80.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.3 million, marking a year-over-year increase of 168.15%. This contributed to the annual value of $29.8 million for FY2024, which is N/A change from last year.
  • Latest data reveals that Stoke Therapeutics reported Long-Term Investments of $80.3 million as of Q3 2025, which was down 25.12% from $107.3 million recorded in Q2 2025.
  • Over the past 5 years, Stoke Therapeutics' Long-Term Investments peaked at $107.3 million during Q2 2025, and registered a low of $23.0 million during Q1 2025.
  • In the last 2 years, Stoke Therapeutics' Long-Term Investments had a median value of $30.0 million in 2024 and averaged $54.1 million.
  • Data for Stoke Therapeutics' Long-Term Investments shows a peak YoY spiked of 168.15% (in 2025) over the last 5 years.
  • Stoke Therapeutics' Long-Term Investments (Quarterly) stood at $29.8 million in 2024, then spiked by 168.15% to $80.3 million in 2025.
  • Its Long-Term Investments stands at $80.3 million for Q3 2025, versus $107.3 million for Q2 2025 and $23.0 million for Q1 2025.